Lit Matters #1: Debunking STEMI Dogma

Right ventricular STEMI is not the nitroglycerin contraindication many of us were taught. In suspected RVMI, nitrate-associated hypotension appears uncommon, transient, and fluid responsive, and current evidence does not show worse adverse events than STEMI in other territories.

Nitroglycerin in Right Ventricular STEMI

• Dogma versus evidence: The classic 'never give nitro in RVMI' rule rests on surprisingly thin historical data, while newer pooled evidence challenges the strength of that contraindication.
• Preload dependence framing: Right ventricular infarction is still a preload-sensitive state, but the feared nitrate effect is usually brief hypotension rather than catastrophic collapse.
• Meta-analysis signal: Across 1,113 patients, pooled data found no meaningful increase in adverse events or death when nitrates were used in RVMI compared with MI elsewhere.
• Typical adverse effect: Hypotension was the main complication, and in the included studies it was generally mild, transient, and responsive to fluids rather than a reason to avoid nitrates outright.
• Practical bedside takeaway: For suspected RVMI within an inferior STEMI, low- to moderate-dose nitroglycerin looks far less dangerous than dogma suggests, and we get into the bedside nuance in the episode.
• Important study limitation: Most included studies grouped right ventricular and inferior MI together, so the evidence is reassuring but not a blank check for every isolated RV infarct scenario.